Filing Details

Accession Number:
0001104659-22-022301
Form Type:
13G Filing
Publication Date:
2022-02-13 19:00:00
Filed By:
Wagenheim Philip
Company:
Immunome Inc.
Filing Date:
2022-02-14
SEC Url:
13G Filing
Ownership Summary

Please notice the below summary table is generated without human intervention and may contain errors. Please refer to the complete filing displayed below for exact figures.

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
Philip Wagenheim 403,698 403,698 3.3%
Filing
 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

SCHEDULE 13G

Under the Securities Exchange Act of 1934

(Amendment No. 1)*

 

Immunome, Inc.

(Name of Issuer)

 

Common Stock, par value $0.0001per share

(Title of Class of Securities)

 

45257U108

(CUSIP Number)

 

December 31, 2021

(Date of Event Which Requires Filing of this Statement)

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

 

¨        Rule 13d-1(b)

 

¨        Rule 13d-1(c)

 

x       Rule 13d-1(d)

 

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

 

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 

 

Schedule 13GPage 2 of 5 Pages
  
CUSIP NO. 45257U108 

 

 

1.Names of Reporting Persons
  
 Philip Wagenheim
  
2.Check the Appropriate Box if a Member of a Group (See Instructions)
 (a)  ¨
 (b)  ¨
  
3.SEC USE ONLY
  
4.Citizenship or Place of Organization
  
 United States of America
   
Number of5.Sole Voting Power
Shares 403,698 shares
Beneficially  
Owned by6.Shared Voting Power
Each None
Reporting  
Person With7.Sole Dispositive Power
  403,698 shares
   
 8.Shared Dispositive Power
  None
9.Aggregate Amount Beneficially Owned by Each Reporting Person
  
 403,698 shares
10.Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨
  
11.Percent of Class Represented by Amount in Row (9)*
  
 3.3%
12.Type of Reporting Person (See Instructions)
  
 IN

 

 

Schedule 13GPage 3 of 5 Pages
  
CUSIP NO. 45257U108 

 

 

Item 1.(a)Name of Issuer:
  
 Immunome, Inc.
  
Item 1.(b)Address of Issuer's Principal Executive Offices:
  
 665 Stockton Drive, Suite 300
 Exton, PA 19341
  
Item 2.(a) Name of Person Filing:
  
 Philip Wagenheim
  
Item 2.(b)Address of Principal Business Office or, if none, Residence:
  
 c/o Immunome, Inc.
 665 Stockton Drive, Suite 300
 Exton, Pennsylvania 19341
  
Item 2.(c)Citizenship:
  
 United States of America
  
Item 2.(d)Title of Class of Securities:
  
 Common Stock, par value $0.0001 per share
  
Item 2.(e)CUSIP Number:
  
 45257U108
  
Item 3.If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

 

(a)  ¨Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o).
(b)  ¨ Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c).
(c)  ¨ Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c).
(d)  ¨ Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
(e)  ¨An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).
(f)  ¨ An employee benefit plan or endowment fund in accordance with §240.13d-(b)(1)(ii)(F).
(g)  ¨ A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G).
(h)  ¨A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813).
(i)  ¨A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3).
(j)  ¨A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J).
(k)  ¨ Group, in accordance with §240.13d-(b)(1)(ii)(K).

 

Not applicable.

 

 

Schedule 13GPage 4 of 5 Pages
  
CUSIP NO. 45257U108 

 

 

Item 4. Ownership.

 

(a)       Amount Beneficially Owned as of December 31, 2021: 403,698 shares (1)

 

(b)       Percent of Class: 3.3% (2)

 

(c)       Number of shares as to which such person has:

 

(i)       Sole power to vote or to direct the vote: 403,698 (1)

(ii)      Shared power to vote or to direct the vote: 0

(iii)     Sole power to dispose or to direct the disposition of: 403,698 (1)

(iv)     Shared power to dispose or to direct the disposition of: 0

 

(1) Includes 6,301 shares issuable pursuant to outstanding options which are currently exercisable.

(2) The percentage of ownership reported in this Schedule 13G is based upon 12,100,387 shares of common stock of the issuer outstanding as reported in the issuer’s Form 10-Q filed with the SEC on November 15, 2021.

 

Item 5. Ownership of Five Percent or Less of a Class.

 

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following. x

 

Item 6. Ownership of More than Five Percent on Behalf of Another Person.

 

Not applicable.

 

Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

 

Not applicable.

 

Item 8. Identification and Classification of Members of the Group.

 

Not applicable.

 

Item 9. Notice of Dissolution of Group.

 

Not applicable.

 

Item 10. Certifications.

 

Not applicable.

 

 

Schedule 13GPage 5 of 5 Pages
  
CUSIP NO. 45257U108 

 

 

SIGNATURE

 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

Date: February 14, 2022 /s/ Philip Wagenheim
    Philip Wagenheim